Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnos… Read more
Bluejay Diagnostics Inc (BJDX) - Total Assets
Latest total assets as of December 2025: $7.12 Million USD
Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) holds total assets worth $7.12 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bluejay Diagnostics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bluejay Diagnostics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Bluejay Diagnostics Inc's total assets of $7.12 Million consist of 76.7% current assets and 23.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bluejay Diagnostics Inc's current assets represent 76.7% of total assets in 2025, an increase from 32.8% in 2019.
- Cash Position: Cash and equivalents constituted 72.6% of total assets in 2025, up from 10.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bluejay Diagnostics Inc Competitors by Total Assets
Key competitors of Bluejay Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Bluejay Diagnostics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bluejay Diagnostics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bluejay Diagnostics Inc is currently not profitable relative to its asset base.
Bluejay Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.88 | 6.05 | 0.28 |
| Quick Ratio | 4.88 | 6.05 | 0.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.34 Million | $ 4.09 Million | $ -2.34 Million |
Bluejay Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between Bluejay Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.53 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 6.9% |
| Total Assets | $7.12 Million |
| Market Capitalization | $1.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bluejay Diagnostics Inc's assets below their book value (0.22 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bluejay Diagnostics Inc's assets grew by 6.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual total assets of Bluejay Diagnostics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.12 Million | +6.94% |
| 2024-12-31 | $6.66 Million | +36.74% |
| 2023-12-31 | $4.87 Million | -63.99% |
| 2022-12-31 | $13.52 Million | -35.67% |
| 2021-12-31 | $21.02 Million | +1285.25% |
| 2020-12-31 | $1.52 Million | +65.55% |
| 2019-12-31 | $916.52K | -- |